MIIM
CPRX

Mesirow Institutional Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Mesirow Institutional Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$15.5M Sell
742,295
-58,503
-7% -$1.26M 1.19% 29
2024
Q3 		$15.9M Sell
800,798
-133,436
-14% -$2.47M 1.22% 26
2024
Q2 		$14.5M Buy
934,234
+215,130
+30% +$3.35M 1.27% 27
2024
Q1 		$11.5M Buy
+719,104
New +$10.8M 1.02% 52

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Mesirow Institutional Investment Management's CPRX Position: Q4 2024 in Review

Mesirow Institutional Investment Management reduced its Catalyst Pharmaceutical (CPRX) stake by 7.3% in Q4 2024, selling an estimated $1.26M and leaving 742,295 shares worth $15.5M. The position accounts for 1.19% of the portfolio, ranked #29.

Mesirow Institutional Investment Management first reported a position in CPRX in Q1 2024 and has held it in 4 quarters since. The position peaked at $15.9M in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • Mesirow Institutional Investment Management held 742,295 shares of Catalyst Pharmaceutical worth $15.5M as of Q4 2024.
  • Mesirow Institutional Investment Management sold 58,503 Catalyst Pharmaceutical shares in Q4 2024, an estimated $1.26M.
  • Catalyst Pharmaceutical made up 1.19% of Mesirow Institutional Investment Management's portfolio in Q4 2024, its #29 holding.
  • Mesirow Institutional Investment Management first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 4 quarters since.
  • Mesirow Institutional Investment Management's Catalyst Pharmaceutical position peaked at $15.9M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Mesirow Institutional Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.